CEO Dan Verde discusses new capitation contracts signed in two states for medical and radiation oncology services, aiming to improve net loss in Q4. The company addresses reimbursement challenges on Part D drugs by negotiating contracts, revisiting agreements, optimizing costs, and renegotiating purchase terms with suppliers.